enhanced_deficit
12-02-2018, 01:24 AM
Is World Peace a sustainable business model for weapons industries (that create many well paying jobs) and for Wall St. war profiteers (who create nothing)?
There is no implication here that violent groups like ISIS and various global wars/bloody civil wars were instigated/induced/birthed by Wall Street linked neocons/ war profiteer cabals etc.
Related
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?' (https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html)
Tae Kim
11 April 2018
https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2017/03/06/104324084-GettyImages-505658023.530x298.jpg?v=1488832659
Yuri Arcurs | Getty Images
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run.
"Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution."
"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."
There is no implication here that violent groups like ISIS and various global wars/bloody civil wars were instigated/induced/birthed by Wall Street linked neocons/ war profiteer cabals etc.
Related
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?' (https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html)
Tae Kim
11 April 2018
https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2017/03/06/104324084-GettyImages-505658023.530x298.jpg?v=1488832659
Yuri Arcurs | Getty Images
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run.
"Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution."
"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."